Heterogeneity in the gene locus for steroid 21-hydroxylase deficiency

GILLIAN RUMSBY*, ANGELA H L FIELDER, WILLIAM M HAGUE, AND JOHN W HONOUR

From the Department of Clinical Biochemistry, Institute of Child Health, London WC1N 1EH; Department of Immunology, Royal Postgraduate Medical School, Hammersmith Hospital, London W12 0HS; and Cobbold Laboratories, The Middlesex Hospital, London W1N 8AA.

SUMMARY DNA was analysed from 33 patients with congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. In each case Southern blots were prepared from a number of restriction enzyme digests and hybridised with probes for both the 21-hydroxylase and the adjacent fourth component of complement (C4).

Evidence for deletion of the active 21-hydroxylase gene (CYP21B) was found in 13 cases and in 10 of these the deletion included the adjacent C4B gene, leading to a hybrid CYP21A/CYP21B gene. Deletion of CYP21B alone was found in one patient, the remaining two cases appearing to have the active gene replaced by the inactive pseudogene. Duplications of the CYP21A–C4B region and deletion of the pseudogene are also described. In a further 12 cases no gross abnormality could be found.

The genes coding for the steroid 21-hydroxylase enzyme (EC 1.14.99.10, CYP21) are located on the short arm of chromosome 6, 3′ to the genes coding for the fourth component of complement, C4A and C4B. Deficiency of this enzyme leads to congenital adrenal hyperplasia (CAH) and has been shown to be caused by a heterogeneous range of defects, including deletions of the active (21-hydroxylase B) gene1–2 and possible point mutations and gene conversions.3–4 This paper summarises the findings in a group of 33 patients with 21-hydroxylase deficiency from 31 families.

Patients

The majority of patients had presented in the neonatal period as salt losers (SL, n=24) or as simple virilisers (SV, n=3). Six had presented as late onset (LO) cases at ages ranging from five to 20 years.
Methods

Genomic DNA was isolated from peripheral blood leucocytes by the method of Bell et al.5 Samples of 10 \( \mu \)g were digested with restriction endonucleases according to the manufacturer’s instructions (Pharmacia Ltd). Digests were separated on 0-75% agarose gels, treated according to Wahl et al.6 and blotted onto nitrocellulose.7 Hybridisation conditions and probes used were as previously described.1 Their location in the C4/21-hydroxylase gene region is shown in fig 1. C4 allotyping was carried out after neuraminidase treatment of EDTA plasma.8

Results

Interpretation of results required the use of all probes and a variety of restriction endonucleases. The fragments these produce are shown in fig 1. Most useful was the analysis of TaqI digests with both probes A and K which gave information on the C4 (A and B) and 21-hydroxylase (CYP21A and B) genes respectively, as described by Schneider et al.9 In addition, a double digest of DNA with the enzymes BglII and EcoRI, as previously described,1 gives information on both the 5’ and 3’ ends of each 21-hydroxylase gene.

Twelve patients (10 SL, 2 LO) had intact C4 and 21-hydroxylase genes on both chromosomes, giving a normal pattern with all enzymes used (fig 2, lane 1).

Homozygous deletions of the active CYP21B locus in this group of patients are rare (1/33) (fig 2, lane 2). This SL patient had a deletion extending from the 3’ end of the 21A gene to the 3’ end of the 21B gene, including the C4B locus, and has been previously described.1 An apparent heterozygous deletion of the same region occurred in a further nine cases (1 SV and 8 SL) (fig 2, lane 3). This was associated with an HLA-B47 haplotype in only two of these cases.

One SL patient appeared to have a deletion of the 21B gene alone. The results of a TaqI digest using probes A and K are shown in fig 2, lane 4. No 3-7 kb band is present with probe K, while probe A shows three bands of 7 kb, 6 kb, and 5-4 kb respectively, the first being of approximately twice the intensity of each of the other two. This indicates that not only is the C4B locus intact, but that both a ‘short’ and ‘long’ C4B gene are present (bands at 6 kb and 5-4 kb).9 The 3 kb Kpn band was also absent. The data suggest either that both chromosomes have a single deleted CYP21B or that there are two CYP21A genes present on each chromosome and no CYP21B gene, that is, gene conversion has occurred. In this particular subject, the 3’ end of the CYP21B gene appears to be unchanged, as a double digest using

---

**FIG 2** Southern blots of TaqI digests of DNA from six patients with 21-hydroxylase deficiency.
**Discussion**

The most important finding in this study is the range of genetic defects which can give rise to the clinical presentation of 21-hydroxylase deficiency. The interpretation of results in these patients is difficult and requires the use of more than one restriction enzyme and probes for both C4 and 21-hydroxylase.

In those cases in which a normal restriction fragment pattern is evident, one can only assume that an undetected point mutation is present in either the gene or flanking sequences. Rodrigues et al. cloned a single intact, but presumably defective, CYP21B gene and found a total of 11 nucleotide differences, two of which were in exons leading to amino acid substitutions in the protein molecule. In the same patient, there was also some evidence for partial 'gene conversion', the defective 21B containing some changes which gave rise to the nucleotide sequence found in the CYP21A gene. Two unrelated patients in our study show evidence of possible gene conversion; in both the characteristics of the 5' end of the 21B gene are missing, the 3' end apparently remaining intact. Similar results were reported by Donohoue et al., Jospe et al., and Harada et al., the latter showing by partial nucleotide sequencing analysis that the 21-hydroxylase B gene has been converted to the pseudogene.

Deletion of the C4A-CYP21A locus in two of our cases may be coincidental, as subjects with homozygous deletion of CYP21A (as in HLA-B8, DR3) are negatively associated with CAH. An undetected fault could lie in the CYP21B genes present.

---

*Figure 3* Southern blots of BglII/EcoRI digests of DNA from patients with 21-hydroxylase deficiency compared with controls (c).
The HLA-B14, DR1 haplotype associated with late onset CAH has been shown to have a duplication of the C4B\(^1\) and CYP21A\(^1\) loci. These findings are confirmed here. It is still not clear, however, why such a duplication should lead to defective enzyme activity in the presence of an apparently normal 21B gene.

In all patients assigned a deleted CYP21B gene in this and our previous study,\(^1\) the deletion was confirmed using several enzymes. With one exception the deletion included the C4B gene (confirmed with probe A). The gene is thus a hybrid with 5' characteristics of the CYP21A and those of the CYP21B gene at the 3' end, as previously described.\(^1\)\(^5\) This point was overlooked by Matteson et al\(^1\) who showed the 3-7 kb Taq fragment to be absent but after other enzyme digests failed to confirm deletion of CYP21B.

In conclusion, gene deletion, conversion, and duplication have been found in 21 of the cases of 21-hydroxylase deficiency described here, with the possibility in the remaining 12 cases of point mutations in the 21-hydroxylase gene.

We are grateful to Dr D B Grant, Dr C G D Brook, and Professor H S Jacobs for allowing us to study their patients. WMH was generously supported as a Clinical Research Fellow by the Frances and Augustus Newman Foundation.

References


Correspondence and requests for reprints to Dr J W Honour, Cobbold Laboratories, Middlesex Hospital, Mortimer Street, London W1N 8AA.